 The FDA offered mixed messages Friday for Amylyx Pharmaceuticals experimental neurological disease treatment, and AMLX stock crashed. The post The FDAs Mixed Messages Sent Amylyx Pharmaceuticals Stock Off A Cliff appeared first on Investors Business Daily. 